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introduction
A critical component of successful patient care in total knee 
arthroplasty (TKA) is a blood management strategy. TKA can 
result in substantial perioperative blood loss, rendering patients 
at increased risk of requiring allogenic blood transfusion1,2). Total 
knee and hip arthroplasty and fracture surgery is the number 
one reason for transfusion in patients undergoing surgery and 
accounts for 9.8% of all transfused red blood cell units3). Compli-
cations of allogenic blood transfusion include the risk of disease 
transmission, hemolytic reaction, fluid and hemodynamic over-
load, acute lung injury, coagulopathy, allergic reaction and febrile 
non-hemolytic reaction4). Allogenic transfusion is associated 
with immunomodulation, and an increased incidence of pros-
thetic infection5,6). Bierbaum et al.7) reported a transfusion rate 
of 39% following TKA, with an increased risk of fluid overload, 
infection rate and duration of hospitalization in the patients who 
received allogenic transfusion. Several studies have highlighted 
the disadvantages of allogenic blood including a negative effect 
on postoperative complications, length of hospital stay, cost and 
mortality8-10).
The fundamental aim of blood management is to eliminate 
the need for allogenic blood whilst at the same time preventing 
anaemia. Thereby the risk of transfusion is removed, hemoglobin 
(Hb) status and oxygen carrying capacity is maximized, leading 
to a positive effect on the patient’s recovery and both early and 
long-term outcomes. Blood management strategies should be 
individualized, based on patient specific risk factors including 
preoperative Hb level, anticipated difficulty of the procedure and 
expected blood loss, and associated medical comorbidities. Hb 
loss in routine primary TKA has been calculated to be 3.8 g/dL11). 
The transfusion trigger should be individualized based on the 
risks and benefits for each patient. Two recently published stud-
ies highlighted the benefits of evidence-based, multidisciplinary, 
multimodal approach to optimizing care in joint replacement pa-
tients potentially requiring allogenic transfusion12,13). Both studies 
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stressed the importance of optimizing preoperative red cell mass, 
minimizing perioperative blood loss and being judicious with 
the threshold for transfusion based on each individual’s clinical 
status. By introducing a multimodal program supported by evi-
dence-based guidelines, transfusion rate was markedly reduced 
with a significant reduction in complications, 30-day readmission 
rates, length of hospital stay and mortality. Available blood man-
agement strategies can be broadly divided into 3 stages: preopera-
tive optimisation, intraoperative and postoperative protocols14). 
The spectrum of available modalities is summarized in Table 1.
preoperative Strategies
Several studies have highlighted the significant influence of pre-
operative Hb on the requirement for transfusion in TKA11,15). Sa-
lido et al.15) demonstrated very few patients with Hb greater than 
150 g/L preoperatively required allogenic blood whilst patients 
with preoperative Hb level less than 110 g/L had a 100% transfu-
sion rate. Similarly, Pierson et al.11) found an algorithm-based 
strategy aimed at improving preoperative Hb level was most ef-
fective in reducing transfusion rate. Other risk factors associated 
with an increased need for transfusion include weight, age greater 
than 75 years, male gender, hypertension and body mass index 
less than 27 kg/cm2 16). Whilst many factors are non-modifiable, 
Pola et al.17) showed more than one risk factor had a compound-
ing effect on transfusion rate. Therefore, in patients with multiple 
risk factors, it is vitally important to correct anaemia and maxi-
mize preoperative red cell mass. Correcting anaemia not only 
reduces the risk of allogenic transfusion but also has a positive 
impact on the patient’s rehabilitation and functional recovery. 
Patients with postoperative Hb between 8 to 10 g/dL may not be 
low enough to warrant transfusion but often feel lethargic, with a 
higher risk of syncopal episodes, impairing their ability to mobi-
lize and undergo rehabilitation.
In our centre, patients are screened 3 months prior to surgery 
with full blood count, proceeding to iron studies if the preopera-
tive Hb is less than 120 g/dL. Any patient identified with anaemia 
is referred to the hematology unit for further investigation of the 
underlying cause and management. A common reason in elderly 
patients is iron deficiency, as a result of poor dietary intake and 
occult gastrointestinal bleeding secondary to non-steroidal anti-
inflammatory drug use. The typical pattern seen in these patients 
is low Hb and low ferritin. The parameters measured to inves-
tigate iron deficiency are listed in Table 2 with threshold cut-off 
values.
Options for maximizing Hb in preparation for surgery include 
iron supplements and erythropoietin. Iron supplements can ei-
ther be given orally or intravenously. Both have been shown to 
be effective, however, oral iron may not be efficacious in patients 
with malabsorption such as coeliac disease. Another disadvan-
tage of oral iron supplements is the slow effect and therefore it 
needs to be implemented well in advance of surgery. A cohort 
Table 1. Summary of Blood Management Interventions Available to Reduce Allogenic Transfusion Rates in Total Knee Arthroplasty Patients
Preoperative Intraoperative Postoperative
Correcting anaemia
    Investigate cause
    Iron supplements
    Erythropoietin
Preoperative autologous blood donation
Ceasing antiplatelet and anticoagulant 
medications
Acute normovolemic haemodilution
Intraoperative cell salvage
Topical fibrin sealant
Tranexamic acid
    Intravenous
    Topical
    Oral
Postoperative cell salvage
Reinfusion drain
No drain use
Tranexamic acid
    Intravenous
    Oral
Evidence-based individualised trigger 
for allogenic transfusion
Table 2. Preoperative Iron Studies and Threshold Values for Iron Defi-
ciency in Patients with Preoperative Anaemia, Requiring Correction 
prior to Total Knee Arthroplasty
Parameter Threshold value
Hemaglobin (g/dL) 12
Hematocrit (%) 0.38
Iron (µmol/L) 5
Total iron binding capacity (µmol/L) 45
Transferrin saturation (%) 20
Ferritin (µg/L) 50
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study of 156 patients treated with ferrous sulfate 256 mg/day for 
1 month preoperatively, in with combination vitamin C which 
enhances iron absorption, showed a reduced transfusion rate 
for non-anemic patients18). For our patients with deficient iron 
stores, the hematologists administer 500–1,000 mg ferritin car-
boxymaltose as a rapid intravenous infusion over 15 minutes. 
Dosage depends on duration and severity of iron deficiency. The 
infusion needs to be given minimum of 3 weeks preoperatively, 
and is expected to improve the Hb 1 g/dL over 10 days. We have 
observed intravenous iron to be more effective than oral supple-
ments (D’Costa E, Unpublished Data). Munoz et al.19) reported a 
significant increase of 1.8 g/dL in Hb level and 67% resolution of 
anaemia using intravenous iron sucrose.
Erythropoietin is a synthetic hormone, stimulating progeni-
tor cells in the bone marrow to differentiate into red blood cells 
and activating hematopoiesis. Erythropoietin is a powerful agent 
in correcting anaemia. In a systematic review, Spahn20) showed 
erythropoietin to be successful in improving mean preoperative 
Hb and postoperative Hb with reduced transfusion rates when 
combined with iron therapy in patients undergoing TKA. The 
main disadvantage of erythropoietin is cost and at this stage, its 
routine use in Australia is not approved in TKA patients unless 
the patient suffers anaemia secondary to chronic renal failure.
An important element of blood conservation in TKA is limiting 
blood loss. Patients undergoing TKA frequently take antiplatelet 
and anticoagulant medications that affect the risk of bleeding. 
The decision and timing of cessation of antiplatelelet and antico-
agulant therapy needs to take into consideration risks of throm-
bosis versus risk of bleeding. Platelet activation occurs with non-
cardiac surgery, making myocardial infarction the most common 
major vascular complication after surgery. Under usual circum-
stances, warfarin should be discontinued 5 days prior to TKA21) 
and recommenced postoperatively when the risks of acute bleed-
ing are believed to be stable. Bridging anticoagulation therapy is 
commonly used in the interim period with agents such as low 
molecular heparin, which has a shorter half-life22). There are no 
clear guidelines or consensus on the optimal bridging therapy 
for patients on warfarin for conditions such as atrial fibrillation, 
previous embolic cerebrovascular events or mechanical valve 
replacement, and further clinical trials are required to clarify the 
optimal regime.
With regards to aspirin and antiplatelet therapy, its cessation 
prior to surgery is believed to result in an increased risk of car-
diovascular complications and major cardiac events23,24). How-
ever, a recent large randomized controlled trial of 10,010 patients 
including 39% orthopaedic procedures, comparing aspirin versus 
placebo with 30-day follow-up after surgery, found conflicting 
results25). There was no difference in the primary outcome of 
death or myocardial infarction between the 2 groups, regardless 
of whether the patient was taking aspirin prior to surgery or not. 
Aspirin increased the risk of major bleeding compared with pla-
cebo. The most common reported site of bleeding was the surgi-
cal site in 78.3% and gastrointestinal tract in 9.3%. The authors 
concluded aspirin administration before surgery and throughout 
the early postsurgical period had no significant effect on the rate 
of composite of death or nonfatal myocardial infarction but in-
creased the risk of major bleeding. We now cease aspirin prior to 
TKA.
Preoperative autologous donation was previously popular in 
elective TKA. Allogeneic transfusion rates were reduced from 
40%–52% to 3%–18% in the preoperative autologous donor 
group in two cohort studies26,27). However preoperative autolo-
gous donation is associated with a high rate of wasted blood 
and is no longer deemed to be cost effective. There remains the 
potential for wrong blood being returned to the patient due to 
clerical errors28,29). The process necessitates the inconvenience of 
donating blood in advance of scheduled surgery. The use of pre-
operative autologous blood donation has therefore fallen out of 
favour and we no longer use it in our TKA patients.
intraoperative Strategies
The risk of intraoperative bleeding is influenced by difficulty of 
the procedure and patient factors such as obesity, comorbidities 
and bleeding disorders. Meticulous efficient surgical technique 
with careful dissection, soft tissue handling and bleeding control 
assists with diminishing blood loss. Maintaining steady blood 
pressure and normothermia are both recommended in reducing 
bleeding. Whilst preventing patient hypothermia is accepted to 
be important in limiting blood loss, we found rigid temperature 
control is not necessary in a prospective consecutive observation-
al cohort study of patients undergoing primary TKA30). As long 
as patient axillary temperature is maintained within the range of 
34.7oC–37.8oC during the perioperative period, our study dem-
onstrated no effect of patient temperature on transfusion rate or 
blood loss. 
The technique of acute normovolemic hemodilution attempts 
to achieve a similar effect to preoperative autologous blood dona-
tion without the preoperative inconvenience. Blood is collected 
from the patient in the immediate preoperative period and vol-
ume is replaced with colloid or crystalloid fluid. The rationale is 
surgical blood loss will have a lower hematocrit, and the collected 
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whole blood is transfused in the immediate postoperative period, 
negating the downsides of blood storage. However, the effective-
ness of acute normovolemic hemodilution in reducing allogenic 
transfusion is debatable20). It may be appropriate in selected cases 
where blood cross matching is difficult due to the presence of an-
tibodies however we do not recommend its routine use.
Perioperative red cell salvage collects blood lost during the 
operative procedure and immediate postoperative period, and 
returns the blood to the patient. This technique has several ad-
vantages over preoperative autologous donation and acute nor-
movolemic hemodilution. Perioperative red cell salvage reinfuses 
fresh blood, thereby avoiding problems associated with storage, 
seen with autologous predonation and allogeneic blood. This 
translates to more efficacious oxygen carrying capacity with a 
higher mean erythrocyte viability31) and increased preservation 
of 2–3 diphosphoglycerate32). Red cell salvage also incorporates 
washing the blood loss volume. Washing the blood removes 
biochemical, cellular and non-cellular debris31). Unwashed cell 
salvage is associated with adverse postoperative effects due to the 
presence of cytokines including hypotension, hyperthermia, in-
creased postoperative bleeding and non-cardiogenic pulmonary 
edema33,34). We have been using intraoperative red cell salvage for 
primary and revision TKA, with success in reducing allogenic 
transfusion requirement (Dan M, Unpublished Data). The effi-
cacy of cell salvage in TKA in our cohort compared to previously 
published studies35-37) is outlined in Table 3. We concluded peri-
operative red cell salvage reduces but does not eliminate the need 
for allogenic blood. The effectiveness of intraoperative red cell 
salvage is dependent on preoperative Hb and hematocrit of blood 
lost and actual blood loss volume, which in turn determine the 
ability to return red cells. We believe intraoperative red cell sal-
vage is most effective in patients with preoperative Hb between 
120 to 150 g/dL, further emphasizing the importance of correct-
ing preoperative Hb above 120 g/dL prior to TKA. Above 150 g/
dL, cell salvage is not usually required as allogenic transfusion 
rate is negligible.
Topical fibrin sealant, composed of fibrinogen and thrombin, 
mimics the final step of coagulation cascade when mixed to-
gether during the application process. Randelli et al.38) performed 
a randomized trial of topical fibrin versus control group in TKA 
and found no difference in Hb levels, postoperative decrease in 
Hb, drainage or mean total blood loss. In particular, the transfu-
sion rate was 32.3% in the control group compared with 25.8% 
in the fibrin group, with no significant difference. The authors 
concluded topical application of fibrin sealant was not effective in 
reducing perioperative blood loss in TKA. Another randomized 
study comparing topical fibrin spray to intravenous tranexamic 
acid (TXA) demonstrated comparable reduction in blood loss 
but the cost of the fibrin spray was significantly greater39). 
postoperative Strategies
The routine use of intra-articular wound drainage in TKA has 
been shown to increase blood transfusion requirement40). This 
needs to be balanced with the reported increased risk of persis-
tent ooze, bruising and hematoma formation41). Evidence for use 
of an intra-articular drain in TKA therefore remains inconclusive 
and very much an individual decision based on surgeon prefer-
ence.
Postoperative reinfusion drains are commonly employed in 
TKA and previous investigations suggest reduction in allogeneic 
transfusion rate. A meta-analysis by Huet et al.33) showed a rela-
tive risk reduction of 0.35 for allogeneic transfusion need with 
reinfusion drains. Zacharopoulos et al.42) performed a prospec-
tive randomized controlled trial with reinfusion drains, demon-
strating a decrease in allogenic blood transfusion. In contrast, 
Hazarika et al.43) showed reinfusion drains had no significant 
benefit with the downside of additional cost. Reinfusion drains 
carry the potential for transfusion reaction, as the unwashed 
blood contains fibrin degradation products and other potential 
contaminants44,45). The drained blood needs to be reinfused with 
6 hours of commencement to avoid the potential for hemolysis. 
We no longer use reinfusion drains, as the cost does not seem to 
be justified, especially with the increasing use of TXA in reducing 
postoperative blood loss.
A multitude of publications have highlighted the use and ben-
efits of antifibrinolytic agents. TXA is one such agent, being a 
synthetic plasminogen-activator inhibitor, showing both clinical 
efficacy and an acceptable safety profile. TXA inhibits the activa-
tion of plasminogen to plasmin by blocking the lysine binding 
sites of plasminogen to fibrin. The result is decrease proteolytic 
action on fibrin monomers and fibrinogen, leading to clot sta-
Table 3. Allogenic Transfusion Rate Using Autologous Reinfusion of Sal-
vaged Blood Cells in Randomized Controlled Trials and Cohort Studies 
on Total Knee Arthroplasty
Study Allogenic transfusion rate (%)
Dan Ma) 11.9
Shenolikar et al.35) 16.0
Thomas et al.36) 7.0
Munoz et al.37) 11.0
a)Unpublished data.
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bilization46). The use of TXA in primary TKA is associated with 
reduced transfusion rates, increased discharge to home, and re-
duced costs47).
TXA has desirable features of ease of administration, minimal 
effect on operative procedure workflow, and extremely low cost 
as a generic medicine. Intravenous TXA has been demonstrated 
to significantly reduce the amount of blood loss and blood trans-
fusion requirements without an increase in venous thromboem-
bolic risk in multiple studies for TKA48,49). 
There is however no clear consensus on ideal dosage, timing, 
frequency and route of administration for TXA in TKA. The cur-
rent recommendation for intravenous use is 10 to 15 mg/kg as a 
single dose. However significant heterogeneity exists in currently 
available studies, with doses ranging from 700 to 10,500 mg and 
often with multiple dosages. Oral TXA has shown similar effec-
tiveness to intravenous50). Several contra-indications preclude the 
use of intravenous TXA at the time of surgery, including renal in-
sufficiency, history of previous deep venous thrombosis, cerebro-
vascular and cardiac disease. One study reported 28% of patients 
were contraindicated to intravenous TXA51) and in these patients 
topical administration may be more appropriate due to delay in 
systemic absorption after application into the knee. Intra-artic-
ular application limits systemic exposure and maximizes drug 
concentration and activity directly at the site of bleeding. Wong 
et al.52) proved the efficacy of intra-articular TXA in a double-
blind, placebo-controlled randomized trial in TKA. The authors 
demonstrated a significant difference in Hb reduction and blood 
loss using 3.0 g of TXA in 100 mL of normal saline compared to 
1.5 g of TXA and placebo, with no difference in thromboembolic 
complications. Plasma levels of TXA following topical adminis-
tration were 70% less than an equivalent intravenous dose. More 
recently, a retrospective study found intra-articular and pericap-
sular injection of TXA after capsular closure resulted in a trans-
fusion rate reduction from 17.5% to 5.5% as well as a significantly 
higher postoperative Hb in the TXA group51). Alshryda et al.53) per-
formed a systematic review and meta-analysis showing topical TXA 
to significantly reduce the rate of blood transfusion and was safe. 
Topical dose in the analysed studies ranged from 250 to 3,000 mg. 
A number of studies have directly compared intravenous TXA 
with topical TXA demonstrating the efficacy and safety of topi-
cal administration in TKA54-56). Both Patel et al.51), using a single 
intravenous dose, and Soni et al.57), using a 3 dose intravenous 
regimen, concluded topical TXA had similar efficacy to intra-
venous TXA in terms of perioperative change in Hb, lowest 
postoperative Hb, total drain output and transfusion rate, and no 
increase in complications in randomized prospective studies. In 
a study comparing 3 methods of administration in TKA, single 
dose intravenous TXA was more effective than topical and intra-
articular TXA injected via the drain in reducing Hb drop58). Lo-
cal administration through the drain yielded least blood drainage 
postoperatively compared to intravenous and topical application, 
with 80% reduction of drainage volume compared to 45% and 
18%, respectively. In contrast, Maniar et al.59) found single intra-
venous dose did not give effective results. A 3-dose regimen of 
preoperative, intraoperative and postoperative doses of 10 mg/
kg produced maximum effective reduction of drain loss and total 
blood loss in TKA. The authors concluded a preoperative dose 
prior to tourniquet inflation was important to inhibit the activa-
tion of the fibrinolysis cascade.
Our preference in TKA is to use topical TXA, with no patients 
contraindicated to its use. 3.0 g of TXA combined with 20 mL 
normal saline is administered to the operative site after prosthesis 
cementation and final washout for 5 minutes. After 5 minutes, 
any residual fluid is removed and wound closure performed 
without further lavage or intra-articular drain insertion. 
appropriate transfusion guidelines
Another principal arm of effective blood management is to 
restrict allogenic transfusion to patients meeting well-established 
transfusion criteria. Adherence to evidence-based transfusion 
guidelines and utilization of appropriate transfusion triggers is 
the key element in achieving this. The recommendations for a re-
strictive transfusion protocol include transfusion in patients with 
Hb<7 g/dL, Hb<8 g/dL in setting of cardiac disease, or specific 
patient situations where additional oxygen carrying capacity is 
needed. Transfusion of a single unit of packed red blood cells at a 
time is advised12).
The blood management strategy algorithm used in our hospital 
is shown in Fig. 1. 
conclusions
A blood management program in TKA aims to reduce allogenic 
transfusion rate and its associated risks, whilst at the same time 
maximizing Hb level and oxygen carrying capacity in the post-
operative period. Effective blood conservation encompasses op-
timizing preoperative red cell mass, salvaging blood lost during 
the perioperative period, minimsing blood loss with hemostatic 
measures and individualizing the transfusion trigger according 
to the patient’s clinical status and medical comorbidities. We use 
a combination of preoperative intravenous iron infusion, intra-
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operative red cell salvage, and topical TXA. A proactive approach 
to blood management will lead to a positive effect on early and 
long-term outcomes and greater success in care of TKA patients. 
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